Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
After finishing at $43.88 in the prior trading day, Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) closed at $39.35, down -10.32%. In other words, the price has decreased by -$10.32 from its previous closing price. On the day, 1.25 million shares were traded. RYTM stock price reached its highest trading level at $41.76 during the session, while it also had its lowest trading level at $37.49.
Ratios:
Our goal is to gain a better understanding of RYTM by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.43 and its Current Ratio is at 5.58. In the meantime, Its Debt-to-Equity ratio is 0.63 whereas as Long-Term Debt/Eq ratio is at 0.63.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Morgan Stanley on December 19, 2023, Upgraded its rating to Overweight and sets its target price to $55 from $29 previously.
On August 01, 2023, BofA Securities Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $22 to $27.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 02 ’24 when German Christopher Paul sold 368 shares for $41.76 per share. The transaction valued at 15,368 led to the insider holds 795 shares of the business.
Shulman Joseph sold 18,235 shares of RYTM for $735,600 on Mar 21 ’24. The Chief Technical Officer now owns 30 shares after completing the transaction at $40.34 per share. On Mar 20 ’24, another insider, Lee Jennifer Kayden, who serves as the EVP, Head of North America of the company, sold 18,235 shares for $38.77 each. As a result, the insider received 707,005 and left with 6,852 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RYTM now has a Market Capitalization of 2399283456 and an Enterprise Value of 2470521856. For the stock, the TTM Price-to-Sale (P/S) ratio is 30.99 while its Price-to-Book (P/B) ratio in mrq is 13.78. Its current Enterprise Value per Revenue stands at 31.907 whereas that against EBITDA is -13.53.
Stock Price History:
Over the past 52 weeks, RYTM has reached a high of $52.57, while it has fallen to a 52-week low of $15.50. The 50-Day Moving Average of the stock is -3.98%, while the 200-Day Moving Average is calculated to be 13.97%.
Shares Statistics:
The stock has traded on average 578.32K shares per day over the past 3-months and 581180 shares per day over the last 10 days, according to various share statistics. A total of 59.43M shares are outstanding, with a floating share count of 53.99M. Insiders hold about 11.45% of the company’s shares, while institutions hold 100.95% stake in the company. Shares short for RYTM as of 1713139200 were 10199930 with a Short Ratio of 17.64, compared to 1710460800 on 9197000. Therefore, it implies a Short% of Shares Outstanding of 10199930 and a Short% of Float of 27.229999999999997.
